The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
The center brings together hands on technology demonstrations, application expertise, and commercial operations
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes
This makes VLCC the sole institution in the country authorised to conduct in-person NCLC exams
The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners
She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River
Subscribe To Our Newsletter & Stay Updated
